http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110257428-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-10022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-10034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10043 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate | 2019-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110257428-B |
| titleOfInvention | Recombinant adenovirus expressing porcine circovirus type 3 ORF2 gene and preparation method and application thereof |
| abstract | The invention relates to the technical field of biology, in particular to a recombinant adenovirus for expressing porcine circovirus type 3 ORF2 gene, a preparation method and application thereof. The invention provides a recombinant adenovirus transfer plasmid and a recombinant adenovirus containing a Cap protein coding gene of PCV 3. According to the invention, high-level secretory expression of the Cap protein of PCV3 is realized through artificial codon optimization and signal peptide selection, the structure and function of the obtained Cap protein of PCV3 are completely consistent with those of a natural state, the immunogenicity of the Cap protein is retained to the greatest extent, and the Cap protein can be better and more quickly identified by antigen presenting cells such as DC and the like. The adenovirus vector vaccine provided by the invention has high immunogenicity and safety, can effectively activate the immune response of organisms, stimulates animals to generate high-level specific antibodies and neutralizing antibodies, and plays an excellent immune protection effect on porcine circovirus. |
| priorityDate | 2019-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.